Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP (Anricofen Cipr)

Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During Endoscopic Retrograde Cholangiopancreatography: A Randomized Controlled Trial

This study aims to compare postoperative recovery quality and safety between anricofen combined with ciprofol and sufentanil combined with ciprofol in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) under non-intubated anesthesia.

This is a single-center, prospective, randomized, controlled study involving patients aged 18-80 years who are scheduled for elective ERCP. A total of 180 participants are planned to be enrolled and randomly assigned in a 1:1 ratio to two groups.

Participants in the anricofen group will receive intravenous anricofen (HSK21542) at a dose of 1 μg/kg before ciprofol induction. Participants in the sufentanil group will receive intravenous sufentanil at a dose of 0.1 μg/kg before ciprofol induction. Both groups will receive ciprofol for anesthesia induction and maintenance.

The primary outcome is the total Quality of Recovery-15 (QoR-15) score at 24 hours after the procedure. Secondary outcomes include postoperative pain scores at different time points, total ciprofol consumption, recovery time, post-anesthesia care unit stay, respiratory and hemodynamic adverse events, postoperative nausea and vomiting, and serious adverse events.

The study is expected to provide clinical evidence on the postoperative recovery quality and safety of these two analgesic regimens for patients undergoing ERCP under non-intubated anesthesia.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

180

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Henan
      • Xinxiang, Henan, Chine
        • Recrutement
        • The First Affiliated Hospital of Henan Medical University

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 80 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

**Inclusion Criteria:**

  1. Aged 18 to 80 years;
  2. American Society of Anesthesiologists (ASA) physical status I to III;
  3. Patients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).

**Exclusion Criteria:**

  1. Pregnancy or lactation;
  2. Obstructive sleep apnea (OSA);
  3. Long-term use of analgesics or psychotropic drugs, or a history of drug abuse;
  4. Coagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
  5. Allergy to any of the study drugs;
  6. Severe cardiac, hepatic, renal, or other major organ diseases;
  7. Mental or cognitive impairment that prevents cooperation with the assessment;
  8. Inability to comply with the study protocol or complete follow-up;
  9. Requirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Anricofen(HSK21542) 1 μg/kg + Ciprofol

Anricofen (HSK21542) is a peripherally restricted κ-opioid receptor agonist. In this study, it is administered intravenously at a dose of 1 μg/kg 3 minutes before ciprofol induction by slow injection.

Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses.

Comparateur actif: Sufentanil 0.1 μg/kg + Ciprofol

Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses.

Sufentanil is an opioid analgesic. In this study, it is used as the active comparator and administered intravenously at a dose of 0.1 μg/kg 3 minutes before ciprofol induction by slow injection.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Quality of Recovery-15 (QoR-15) Score at 24 Hours Postoperatively
Délai: 24 hours after the procedure

The primary outcome is the total score of the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours after ERCP. The QoR-15 is a patient-reported measure of postoperative recovery quality, with total scores ranging from 0 to 150. Higher scores indicate better postoperative recovery quality.

24 hours after the procedure

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Resting Numerical Rating Scale (NRS) Pain Score
Délai: At prespecified time points postoperatively

Resting pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), at the prespecified postoperative assessment time points.

At prespecified time points postoperatively
Total Ciprofol Consumption
Délai: During the ERCP procedure

The total dose of ciprofol administered to each participant during the ERCP procedure will be recorded and compared between the two groups.

During the ERCP procedure
Respiratory and Hemodynamic Adverse Events
Délai: During the procedure and up to 24 hours postoperatively

The incidence and details of perioperative respiratory and hemodynamic adverse events will be recorded. Respiratory events include hypoxemia, apnea or significant hypoventilation, airway interventions, mask-assisted ventilation, supraglottic airway placement, and emergency tracheal intubation. Hemodynamic events include hypotension, bradycardia, and the use of vasoactive drugs such as norepinephrine or atropine.

During the procedure and up to 24 hours postoperatively
Postoperative Nausea and Vomiting (PONV)
Délai: Within 24 hours postoperatively

The occurrence of postoperative nausea and vomiting will be recorded and compared between the two groups.

Within 24 hours postoperatively
Serious Adverse Events (SAEs)
Délai: From enrollment until the end of the study

The occurrence, type, and details of serious adverse events will be recorded throughout the study period.

From enrollment until the end of the study
Recovery Time
Délai: From the end of the ERCP procedure to recovery

The time required for participants to recover from anesthesia after the ERCP procedure will be recorded and compared between the two groups.

From the end of the ERCP procedure to recovery
Post-Anesthesia Care Unit (PACU) Length of Stay
Délai: From PACU admission to PACU discharge

The duration of stay in the post-anesthesia care unit (PACU) after the procedure will be recorded and compared between the two groups.

From PACU admission to PACU discharge

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 janvier 2026

Achèvement primaire (Estimé)

1 mars 2028

Achèvement de l'étude (Estimé)

1 mai 2028

Dates d'inscription aux études

Première soumission

16 janvier 2026

Première soumission répondant aux critères de contrôle qualité

26 janvier 2026

Première publication (Réel)

29 janvier 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • XYFY-IIT-ANES-ERCP-2025-01

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner